Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2023-12, Vol.12 (1), p.2201147
Hauptverfasser:	Blomberg, Olga S, Kos, Kevin, Spagnuolo, Lorenzo, Isaeva, Olga I, Garner, Hannah, Wellenstein, Max D, Bakker, Noor, Duits, Danique E M, Kersten, Kelly, Klarenbeek, Sjoerd, Hau, Cheei-Sing, Kaldenbach, Daphne, Raeven, Elisabeth A M, Vrijland, Kim, Kok, Marleen, de Visser, Karin E
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Breast Neoplasms - immunology Breast Neoplasms - therapy CD8-Positive T-Lymphocytes - immunology Humans Immune Checkpoint Inhibitors - therapeutic use Killer Cells, Natural - immunology Lymphocyte Activation Mice Myeloid Cells - immunology Neoadjuvant Therapy Neoplasm Metastasis T-Lymphocytes, Regulatory - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!